Docs not fans of Valeant-Allergan mix

Share this article:

The Allergan-Valeant fight is already changing how doctors think about their prescription habits.

The Wall Street Journal reports that 44% of dermatologists and plastic surgeons polled in a Sanford Bernstein survey said they would consider Botox alternatives if Allergan becomes a Valeant subsidiary.

Bernstein analyst Ronnie Gal created the survey and notes that the answers are all well and good, but doctors have few alternatives.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.